For instance, lncRNA HULC is upregulated in hepatocellular carcinoma and enhances hepatocarcinogenesis by promoting the phosphorylation of YB-1 via the ERK pathway [5]; lncRNA ANRIL alleviates liver fibrosis and hepatic stellate cell (HSC) activation via the AMPK pathway [6]; and lncRNA CCAT1 promotes nonalcoholic fatty liver disease (NAFLD) by increasing LXRα transcription [7]. This evidence concerns the gene CDKN2B-AS1 and metabolic dysfunction-associated steatotic liver disease.